- State programs could modify formularies
- DHCS may have to disregard measure’s price ceiling
For reprint and licensing requests for this article, click here.
More From Employee Benefit News
What Trump’s ‘Great Healthcare Plan’ means for drug costs and price transparency
The legislation calls on Congress to lower prescription drug costs, shift subsidies directly to consumers, and enforce strict price transparency.
GLP-1s push health plan costs to 15-year high
Rising use of the weight-loss drug is fueling the fastest health plan cost growth in a decade and a half, forcing employers to rethink coverage strategies and cost management.
Benefits Think Preparing benefits for the next wave: Gene therapy medications
As the scope of gene therapy grows, understanding their impact and cost can help organizations decide how to cover them through their healthcare plans.
Benefits Think Inside Medicare’s new GLP-1 demonstration
A look at what the Medicare GLP-1 Bridge Program covers, what it doesn't, and what plan sponsors need to know.
As GLP-1 costs climb, more employers weigh dropping coverage in 2027
A growing share of employers are rethinking coverage of the weight-loss drugs as costs rise and early expectations of lower obesity rates and surgical needs have yet to surface in claims data.
